Samsung BioLogics’ 'Super Plant' Reflects Robust Global COVID-19 R&D

Contract Manufacturing Demand Surging

 
• By Jung Won Shin
  
Samsung BioLogics HQ
Investment, Capacity Of Samsung's Fourth Plant Bigger Than Expected • Source: Samsung BioLogics
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

More from Focus On Asia